

ASX Announcement

Bonus Canadian Scientific Research & Experimental Development Rebate Received

SYDNEY Australia, 5 July, 2021: Recce Pharmaceuticals Ltd (**ASX: RCE FSE: R9Q**), the Company developing New Classes of Synthetic Anti-Infectives, is pleased to announce its first international cash receipt of **A\$176,870** from the Canadian Government as part of its Scientific Research & Experimental Development (SR&ED) Tax Incentive program.

The Canadian government's 10% Research and Development (R&D) rebate is in addition to the Australian government's 43.5% R&D Tax Incentive Program. The Company will further claim 43.5% of the total R&D in Canada, and around the world, during Australia's Financial year.

The Australian government's 43.5% R&D tax incentive scheme (otherwise legislatively reserved for domestic R&D only) granted the Company a geographical extension (globally) with financial rebate guarantee to AU\$26,787,500, via the award of two Advanced Overseas Findings to the Company in support of its Synthetic Anti-infective Development, over a period of three years (1 July 2019 to 30 June 2022).

The Advanced Overseas Finding is a pillar of the R&D Tax Incentive Program administered by the Australian Government. The SR&ED program is administered by the Canada Revenue Agency and is aimed at incentivising businesses to conduct R&D in Canada; encouraging innovation and technological advancements.

The filing of Australian rebate is being prepared and is expected to be submitted soon. The Company expects the R&D rebate figures to grow in-line with expanding activities, and thanks the Canadian government for the addition of their support.

This announcement has been approved for release by Recce Pharmaceuticals CEO.



ASX: RCE, **FSE:** R9Q

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327, RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE[®] 327 has been included on The Pew Charitable Trusts *Global New Antibiotics in Development Pipeline* as the only synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

recce.com.au
ACN 124 849 065